Verrica 10-Q: Record YCANTH Revenue, but Going-Concern Warning as Cash Falls to $14.4M
VRCA sits 26% above its 52-week low of $3.08.
Summary
Verrica's Q3 10-Q shows record YCANTH revenue of $5.7 million, but also a $35.2 million nine-month net loss, $14.4 million of cash, and an explicit going-concern warning; runway depends on the remaining $15 million of related-party credit.
Key Events · Earnings and Guidance · VRCA
-
Q3 YCANTH Revenue Hits $5.7M
Product revenue, net rose to $5.7 million for the three months ended September 30, 2026, from $3.6 million a year earlier; nine-month product revenue was $15.1 million versus $11.6 million.
-
Going-Concern Warning on $14.4M Cash
Cash fell to $14.4 million from $30.1 million at December 31, 2025, while operating activities used $27.5 million in the first nine months; management concluded substantial doubt exists about continuing as a going concern within one year.
-
Runway to Q4 2027 With Related-Party Loan
The $27.5 million PD Credit Agreement with Chairman Paul Manning's PD Joint Holdings has $12.5 million drawn and $15.0 million available after October 22, 2026 milestones; combined with cash, management projects funding into the fourth quarter of 2027.
-
R&D Spend Jumps on Common Warts
Research and development expense was $17.5 million for the nine months, up $11.1 million, including $9.0 million of common warts program costs; Q3 R&D alone was $7.6 million versus $2.2 million.
Analysis · VRCA · Life Sciences
Product revenue is genuinely improving — $5.7 million in Q3, up from $3.6 million a year ago — yet the company still burns far more than it sells. Nine-month operating cash use was $27.5 million against $14.4 million of cash on hand, and management states substantial doubt about continuing as a going concern within a year. The lifeline is the $27.5 million PD Credit Agreement from Chairman Paul Manning's entity, of which $12.5 million is drawn and $15.0 million became available October 22, 2026; that plus existing cash is projected to fund operations only into Q4 2027. One overhang is removed by the $4.0 million securities class-action settlement (net $1.7 million after insurance), but the balance sheet now shows a $5.97 million stockholders' deficit, and the Form S-3 baby-shelf limit constrains how much equity can be raised until public float exceeds $75 million.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRCA was trading at $3.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.9M. The 52-week trading range was $3.08 to $9.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.